| Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment Z Gao, Y Bai, A Lin, A Jiang, C Zhou, Q Cheng, Z Liu, X Chen, J Zhang, ... Molecular Cancer 22 (1), 31, 2023 | 37 | 2023 |
| CCNA2 as an immunological biomarker encompassing tumor microenvironment and therapeutic response in multiple cancer types A Jiang, Y Zhou, W Gong, X Pan, X Gan, Z Wu, B Liu, L Qu, L Wang Oxidative Medicine and Cellular Longevity 2022 (1), 5910575, 2022 | 30 | 2022 |
| The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy C Shi, K Qin, A Lin, A Jiang, Q Cheng, Z Liu, J Zhang, P Luo Journal of Experimental & Clinical Cancer Research 41 (1), 268, 2022 | 29 | 2022 |
| Establishment of a prognosis prediction model based on pyroptosis-related signatures associated with the immune microenvironment and molecular heterogeneity in clear cell renal … A Jiang, J Meng, Y Bao, A Wang, W Gong, X Gan, J Wang, Y Bao, Z Wu, ... Frontiers in oncology 11, 755212, 2021 | 29 | 2021 |
| Identification and Verification of m7G Modification Patterns and Characterization of Tumor Microenvironment Infiltration via Multi-Omics Analysis in Clear Cell … K Dong, D Gu, J Shi, Y Bao, Z Fu, Y Fang, L Qu, W Zhu, A Jiang, L Wang Frontiers in Immunology 13, 874792, 2022 | 21 | 2022 |
| DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma Y Bao, A Jiang, K Dong, X Gan, W Gong, Z Wu, B Liu, Y Bao, J Wang, ... International Journal of Biological Sciences 17 (12), 3158, 2021 | 20 | 2021 |
| EGFR‐AS1 promotes bladder cancer progression by upregulating EGFR A Wang, A Jiang, X Gan, Z Wang, J Huang, K Dong, B Liu, L Wang, ... BioMed Research International 2020 (1), 6665974, 2020 | 20 | 2020 |
| Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database C Zhou, S Peng, A Lin, A Jiang, Y Peng, T Gu, Z Liu, Q Cheng, J Zhang, ... EClinicalMedicine 59, 2023 | 19 | 2023 |
| Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis T Gu, A Jiang, C Zhou, A Lin, Q Cheng, Z Liu, J Zhang, P Luo International Journal of Cancer 152 (3), 480-495, 2023 | 17 | 2023 |
| Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome via Effecting Tumor Immunity for ccRCC, Is Related to Cell Invasion, Metastasis … A Jiang, J Meng, W Gong, Z Zhang, X Gan, J Wang, Z Wu, B Liu, L Qu, ... Frontiers in Immunology 13, 842069, 2022 | 17 | 2022 |
| A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma A Jiang, P Luo, M Chen, Y Fang, B Liu, Z Wu, L Qu, A Wang, L Wang, ... Cell & Bioscience 12 (1), 209, 2022 | 10 | 2022 |
| Establishment of a prognostic prediction and drug selection model for patients with clear cell renal cell carcinoma by multiomics data analysis A Jiang, Y Bao, A Wang, W Gong, X Gan, J Wang, Y Bao, Z Wu, B Liu, ... Oxidative medicine and cellular longevity 2022 (1), 3617775, 2022 | 10 | 2022 |
| [Retracted] PTBP1 as a Promising Predictor of Poor Prognosis by Regulating Cell Proliferation, Immunosuppression, and Drug Sensitivity in SARC H Gong, A Jiang, R Jiang, Y Wang, D Zhang, Z Wu, J Xiao Oxidative Medicine and Cellular Longevity 2022 (1), 5687238, 2022 | 10 | 2022 |
| Copper death inducer, FDX1, as a prognostic biomarker reshaping tumor immunity in clear cell renal cell carcinoma A Jiang, J Ye, Y Zhou, B Zhu, J Lu, S Ge, L Qu, J Xiao, L Wang, C Cai Cells 12 (3), 349, 2023 | 7 | 2023 |
| A new thinking: Deciphering the aberrance and clinical implication of IGF axis regulation pattern in clear cell renal cell carcinoma A Jiang, X Wu, D Wang, A Wang, K Dong, B Liu, L Qu, P Luo, J Wang, ... Frontiers in Immunology 13, 935595, 2022 | 6 | 2022 |
| A novel thinking: DDR axis refines the classification of ccRCC with distinctive prognosis, multi omics landscape and management strategy A Jiang, J Song, X Fang, Y Fang, Z Wang, B Liu, Z Wu, L Qu, P Luo, ... Frontiers in Public Health 10, 1029509, 2022 | 5 | 2022 |
| Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy J Meng, A Jiang, X Lu, D Gu, Q Ge, S Bai, Y Zhou, J Zhou, Z Hao, F Yan, ... iMeta 2 (4), e147, 2023 | 4 | 2023 |
| RNA modification pattern‐based subtypes reveal heterogenous clinical outcomes and tumor immunity of clear cell renal cell carcinoma A Jiang, Z Xu, X Fang, D Gu, K Dong, Z Wu, X Gan, B Liu, S Ge, L Qu, ... MedComm–Future Medicine 2 (1), e30, 2023 | 3 | 2023 |
| Definition and verification of novel metastasis and recurrence related signatures of ccRCC: A multicohort study A Jiang, Q Pang, X Gan, A Wang, Z Wu, B Liu, P Luo, L Qu, L Wang Cancer Innovation 1 (2), 146-167, 2022 | 3 | 2022 |
| Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort study L Qu, H Chen, Q Chen, S Ge, A Jiang, N Yu, Y Zhou, M Kunc, Y Zhou, ... MedComm 4 (4), e300, 2023 | 2 | 2023 |
